Outset Medical Names Nabeel Ahmed as Chief Financial Officer
05 Août 2021 - 10:01PM
Business Wire
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical
technology company pioneering a first-of-its-kind technology to
reduce the cost and complexity of dialysis, today announced that
Nabeel Ahmed, currently serving as Outset’s Interim Chief Financial
Officer, has transitioned to the permanent role of Chief Financial
Officer, effective immediately.
“Nabeel’s extensive experience across a variety of finance roles
and his tenure as a leader at Outset give me great confidence in
his ability to lead as Chief Financial Officer,” said Leslie Trigg,
President and Chief Executive Officer. “I look forward to working
closely with him as a member of the executive team as we continue
to execute on our mission while delivering meaningful shareholder
and stakeholder value.”
“I am thrilled to step into this role at such an exciting time
for Outset,” said Nabeel Ahmed, Chief Financial Officer. “Our team,
technology, and growth potential position us uniquely and I look
forward to working toward continued success as we further scale
commercially and operationally.”
Nabeel joined Outset in May 2020 as the company’s Vice
President, Controller and has served as Interim Chief Financial
Officer since July 16, 2021. Prior to joining the company, Nabeel
served as Vice President, Finance at 8x8, Inc. (NYSE: EGHT), a
communications platform provider and as Vice President, Finance at
Vocera Communications, Inc. (NYSE: VCRA). Previously, he held
various leadership positions in accounting and finance, including
as CFO of Wanderful Media as well as CFO of MarketTools, Inc.
Earlier in his career, Nabeel held various positions of increasing
responsibility at Ernst & Young LLP and eBay, Inc. (NASDAQ:
EBAY). Mr. Ahmed holds a Bachelor of Commerce from Laurentian
University and an MBA from The Wharton School, University of
Pennsylvania.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a
first-of-its-kind technology to reduce the cost and complexity of
dialysis. The Tablo Hemodialysis System, FDA cleared for use from
the hospital to the home, represents a significant technological
advancement that transforms the dialysis experience for patients
and operationally simplifies it for providers. Tablo serves as a
single enterprise solution that can be utilized across the
continuum of care, allowing dialysis to be delivered anytime,
anywhere and by anyone. The integration of water purification and
on-demand dialysate production enables Tablo to serve as a dialysis
clinic on wheels, with 2-way wireless data transmission and a
proprietary data analytics platform powering a new holistic
approach to dialysis care. Tablo is a registered trademark of
Outset Medical, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210805006041/en/
Lynn Lewis or Brian Johnston Gilmartin Group
investors@outsetmedical.com
Grupo Aeroportuario del ... (NASDAQ:OMAB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Grupo Aeroportuario del ... (NASDAQ:OMAB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024